Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
Goldman on Pfizer (PFE) Post Metsera (MTSR) Deal: 'previously emphasized the importance of growing its footprint in internal medicines and primary care'
September 22, 2025 10:27 AM EDTGoldman Sachs analyst Asad Haider reiterated a Neutral rating and $27.00 price target on Pfizer (NYSE: PFE).
The analyst comments "This morning PFE announced plans to acquire Metsera (MTSR), a development stage obesity-focused biotech company with a portfolio of candidates (injectable and oral... More
Wolfe Research Comments on Path Forward for Pfizer (PFE) and Metsera (MTSR)
September 22, 2025 9:45 AM EDTWolfe Research analyst Alexandria Hammond reiterated an Underperform rating and $25.00 price target on Pfizer (NYSE: PFE).
The analyst comments "The path forward for Pfizer and Metsera. Topline data from VESPER-1 and interim data from VESPER-3 for MET-097i remain expected by the end of the month. It is our understanding,... More
